Psilocybin-assisted Therapy for End-of-Life Distress

Apr 28, 2021
Online

Description

Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating:

At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.

In this presentation, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology, we explore:

  • Formation of the NYU study
  • Gabby’s role in the study
  • How volunteers were selected
  • Inclusion and admission criteria
  • Study results
  • Can psilocybin help those who are facing death?
  • Current research that Gabby is part of and co-leading
  • How to get involved in the psychedelic field
  • Dreams and visions for the future of psychedelics and psychedelic research

Locations

Exhibitors / Speakers

Last updated: Jan 01, 2021